• ONAR’s core focus is to accelerate revenue for middle-market companies via AI technology, innovation and digital excellence
• CEO notes that middle-market companies are in one of the most exciting yet demanding phases of growth
• ONAR follows a business model designed to be fast-moving, flexible and focused on delivering results, precisely what the middle-market sector needs

ONAR Holding Corp. (OTCQB: ONAR) is staking its claim as a leader in AI-driven marketing, as CEO Claude Zdanow discusses the company’s powerful strategy to support middle-market firms through intelligent, data-focused innovation. In a recent Digital Journal interview, Zdanow detailed ONAR’s mission to deliver integrated, tech-first marketing solutions tailored to growth-stage enterprises (ibn.fm/9ysN6).

Throughout the conversation, Zdanow emphasized ONAR’s core focus: accelerating revenue for middle-market companies via artificial intelligence (“AI”), innovation and digital excellence. “ONAR is a marketing technology company and agency network built specifically for middle-market businesses that are ready to grow,” stated Zdanow. “We sit in a unique space that’s not quite a traditional agency and not just a SaaS platform, but something in between. Our model blends strategic services, AI-driven insights and scalable execution to give companies the tools and support they need to scale quickly and smartly.”

Zdanow noted that middle-market companies are in one of the most exciting yet demanding phases of growth. “They need to scale quickly, perform under pressure and often do more with less. While they’re too large for DIY marketing tools, they’re too lean to rely on massive agency teams. That’s where ONAR’s network comes in and fills the gap,” he said.

Zdanow explained that ONAR follows a business model designed to be fast-moving, flexible and focused on delivering results, precisely what this sector needs. “Middle-market leaders are builders who need partners that can keep pace with their needs, not overengineered solutions or slow-moving firms,” he stated. “They want agility and expertise, which is exactly what our agencies provide.”

ONAR recognizes that these companies are a key element of the economy, but they often face a challenge: they need sophisticated solutions but lack the resources for enterprise-level agency relationships. “ONAR bridges that gap by combining top-tier strategic thinking with the agility, transparency and cost-efficiency that middle-market businesses need,” Zdanow said. “Our agencies’ clients aren’t just looking for a vendor, they want a partner who truly understands their stage and speed.”

“ONAR is purpose-built for the middle market, where innovation meets hustle,” he continued. “Having built businesses from the ground up, we know that these companies need nimble, high-touch support, not complex, overcomplicated solutions. We provide deep expertise and enterprise-grade capabilities without red tape, moving at their speed, speaking their language and staying deeply invested in their success.”

ONAR Holding Corporation is leading a dynamic transformation in how middle-market businesses harness marketing technology. From a foundation in marketing to a robust future-driven strategy rooted in AI, ONAR’s story reflects the power of data, digital innovation and targeted agency partnerships. The company’s innovative ONAR Labs, a dedicated division focused on identifying, developing and commercializing innovative marketing technology solutions, the company is well-positioned to lead the next wave of AI-driven marketing innovation, making middle-market excellence a scalable reality.

For more information, visit the company’s website at www.ONAR.com.

NOTE TO INVESTORS: The latest news and updates relating to ONAR are available in the company’s newsroom at https://ibn.fm/ONAR

• FAVO recently secured an $8 million equity investment to fund growth and accelerate its plan to uplist to the Nasdaq Capital Market
•  The company voluntarily converted all super voting Series C Preferred Shares, simplifying its capital structure and improving governance transparency
• With SMBs turning away from traditional banks, FAVO’s revenue-based lending platform meets rising demand for fast, flexible funding solutions

As inflationary pressures and elevated interest rates strain traditional financing channels, small and medium-sized businesses (“SMBs”) are increasingly seeking alternative funding sources to maintain liquidity and drive growth. Bank approval rates for SMB loans have dropped significantly – from 83% in 2019 to just 68% in 2022 – creating a wide credit gap. This shift has accelerated demand for alternative lending options like merchant cash advances (“MCAs”) and revenue-based financing (“RBF”), which offer faster, more flexible access to capital.

Within this expanding sector, FAVO Capital (OTC: FAVO) stands out as a fintech-driven private credit firm built specifically to meet the evolving needs of underserved SMBs. The company has a multi-prong digital approach, including the development of an advanced digital platform designed to enhance client engagement and streamline funding processes.

Now, with fresh capital and governance reforms, FAVO is preparing for its next big milestone: an uplisting to the Nasdaq Capital Market.

Institutional Confidence Bolsters Growth Strategy

On May 6, 2025, FAVO Capital announced an $8 million Series A Preferred equity investment from Stewards Investment Capital, a global asset manager specializing in fintech and private credit. The investment is a clear signal of institutional confidence in FAVO’s growth trajectory, platform scalability, and strategic vision.

“This funding further positions us to serve the capital needs of underserved SMBs with speed, flexibility, and transparency,” said FAVO CEO Vincent Napolitano. The investment will be used to accelerate SMB lending, strengthen the company’s balance sheet, and expand embedded lending partnerships. It also allows FAVO to restructure a portion of its outstanding debt, increasing its financial agility ahead of its planned Nasdaq uplisting.

Governance Overhaul Reflects Public Market Readiness

Just a week after the funding news, FAVO took another major step toward its Nasdaq ambitions by announcing the voluntary conversion of all outstanding Super Voting Series C Preferred Shares into common stock. This move simplifies the company’s capital structure and aligns voting rights with shareholder-friendly governance standards expected on senior exchanges.

“Converting our Series C Super Voting Shares demonstrates our commitment to transparency, governance and best practices,” said Napolitano. “It’s another important step forward as we align our structure with shareholder and institutional investor expectations.”

By eliminating super voting rights, FAVO has increased accessibility and reduced barriers for potential institutional investors, a crucial element for long-term capital market success.

Riding a Multi-Billion Dollar Lending Wave

The timing of FAVO’s expansion couldn’t be more favorable. The MCA market, valued at $19 billion in 2021, more than doubled from five years prior. Meanwhile, the RBF market is expected to grow from $4.75 billion in 2025 to $14.5 billion by 2034, according to recent projections.

FAVO’s fintech-first approach allows for quick underwriting, dynamic risk assessment, and loan structuring that reflects real-time business conditions far beyond the rigid credit models of traditional banks. With over 10,000 SMBs already served, the company has built a scalable foundation for national growth.

As economic volatility persists and access to bank credit remains constrained, businesses are prioritizing flexibility, speed, and financial partners who understand their day-to-day cash flow dynamics. FAVO’s revenue-based financing options offer exactly that, tying repayments to company revenue and easing pressure during slower months.

Positioned for Public Market Momentum

With a simplified share structure, new institutional capital, and an increasingly vital service offering, FAVO Capital is methodically laying the groundwork for a Nasdaq uplisting. Such a move would elevate the company’s visibility, attract new classes of investors, and unlock greater access to capital for continued expansion.

As SMBs continue to seek more agile, non-bank financing partners, FAVO Capital appears well-positioned to meet that demand while simultaneously transitioning from a small OTC company to a player with national ambitions and institutional credibility.

For more information, visit the company’s website at FAVOCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

• Italian football club Juve Stabia finished 5th in Serie B and reached the semifinals of the Serie A promotion playoffs, recording the highest market value increase in Serie B since March 2025.
• Brera now holds a 38.46% stake in the club, with full FIGC approval for the acquisition.
• Attendance surged, with one match nearly selling out the 7,100-seat stadium, as Juve Stabia games have gained international attention, with broadcasts in the U.S., U.K., and Canada.
• A €5 million (US$5.85 million) subsidy was announced by the Campagna Region for Romeo Menti Stadium refurbishment.

Brera Holdings (NASDAQ: BREA), an Ireland-based international holding company focused on expanding its global portfolio of men’s and women’s sports clubs through a multi-club ownership (“MCO”) strategy, is celebrating the strong performance of its Italian football portfolio club, SS Juve Stabia, which reached the semifinals of the Serie A promotion playoffs after finishing fifth in Italy’s Serie B regular season (https://ibn.fm/jhXA6).

Brera agreed to acquire a controlling interest in Juve Stabia in December 2024. Its most recent step in the acquisition was completed in February 2025, giving Brera a 38.46% stake at present. The move received formal approval from the Italian Football Federation (“FIGC”), underscoring compliance with national football governance standards.

As reported by Italian publication MediaNews24, Castellammare di Stabia city officials, fans, and players gathered recently to recognize the club’s standout season. During the celebration, Mayor Luigi Vicinanza announced that the Campagna Region would allocate €5 million (approximately US$5.85 million) toward upgrades for Juve Stabia’s Romeo Menti Stadium (https://ibn.fm/jYbMP).

Brera’s Executive Chairman, Daniel McClory, attributes the uptick to operational improvements and a focused development strategy. “This extraordinary growth reflects both the untapped potential of Juve Stabia and Brera’s value-creation strategy in action,” McClory said. “Our focus on operational alignment, player development, and shareholder governance is already bearing fruit. We’re proud of the progress and even more excited for what lies ahead.”

Fan engagement has also grown. On April 5, Juve Stabia recorded its highest home attendance of the season, drawing 7,000 spectators, just short of the 7,100-seat capacity of the Romeo Menti Stadium (https://ibn.fm/PRH3P).

The club’s growing visibility was further reflected in international broadcasting of its matches, including live coverage of a recent fixture against Cremonese in the U.S., U.K., and Canada (https://ibn.fm/UJ69J).

Juve Stabia, nicknamed “Le Vespe” (The Wasps) and often referred to as the “Second Team of Naples,” has become a focal point in Brera’s strategy to build a scalable sports investment portfolio. The near-promotion to Serie A, Italy’s top-tier football league, highlights both competitive potential and commercial opportunity.

Brera’s approach emphasizes long-term value, operational governance, and community engagement. Its investment in Juve Stabia appears to be paying early dividends, not only in performance but also in raising the club’s market profile.

“Brera Holdings is proud to be a significant shareholder of Juve Stabia and congratulates Le Vespe and their supporters for an outstanding return to Serie B, and a breathtaking run into the Serie A playoffs,” said McClory. “The future is very bright for the pride of Castellammare di Stabia.”

For more information, visit the company’s website at www.BreraHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to BREA are available in the company’s newsroom at https://ibn.fm/BREA

• Financial momentum for Nutriband is indicated by its recent Q1 financial report
• Progress continues development of proprietary AVERSA(TM) Fentanyl, notes quarterly report
• AVERSA(TM) Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch

A wave of positive developments continues to build momentum for Nutriband (NASDAQ: NTRB), with recent capital funding, strategic partnerships and an expanded intellectual property portfolio reinforcing its bid to lead in the development of safer transdermal therapies. Nutriband is positioning itself at the forefront of abuse-deterrent drug delivery by advancing its Aversa platforms, notably its flagship fentanyl patch and buprenorphine candidates.

Financial momentum for Nutriband is indicated by its recent Q1 financial report (ibn.fm/8R0ca), which noted that the company posted record Q1 2025 revenue of $667,000 — a 63% year-over-year increase — driven by expansion in its kinesiology tape manufacturing via subsidiary Pocono Pharma and growing retail sales at Target, Walmart, Walgreens and CVS.

The company also reported that it is continuing to expand its kinesiology tape output through its Pocono Pharma subsidiary, with a continued focus on penetration pricing to gain a foothold with some of the industry’s largest brands. “Progress continues on the development of AVERSA Fentanyl, with the company formalizing an exclusive product development partnership with Kindeva Drug Delivery,” the report stated. “The formalized partnership with Kindeva Drug Delivery reflects a commitment to shared development costs in exchange for milestone payments, enabling Nutriband to advance its innovative transdermal drug-delivery solutions towards regulatory approval and commercialization.”

The company’s momentum began last year with a notable milestone: the closing of an $8.4 million private placement earmarked to fund AVERSA(TM) Fentanyl’s full-scale commercial development ahead of an expected 2025 NDA submission (ibn.fm/9SZ8B). The company is working with Kindeva, an FDA-approved contract development and manufacturing organization (“CDMO”), to integrate its transdermal abuse-deterrent technology into Kindeva’s existing fentanyl patch. The goal is a best-in-class 505(b)(2) application supported by a single phase 1 human abuse-potential study, bypassing the usual phase 2 and 3 trials.

“AVERSA Fentanyl has the potential to be the world’s first abuse-deterrent opioid patch designed to deter the abuse and misuse and reduce the risk of accidental exposure of transdermal fentanyl patches,” the company stated. “AVERSA(TM) Fentanyl has the potential to reach peak annual U.S. sales of $80 million to $200 million.”

Alongside fentanyl, Nutriband is advancing AVERSA(TM) Buprenorphine, projected to achieve peak U.S. sales between $70 million and $130 million upon approval (https://ibn.fm/mIHdw). Like its counterpart, AVERSA Buprenorphine benefits from Nutriband’s scalable abuse-deterrent platform, and the technology is being positioned for global patent protection.

Nutriband’s forward trajectory is clear: combining transdermal innovation with abuse-deterrent science to meet critical public health needs. With its commercial infrastructure and pipeline expansion, the company is paving a path toward safer opioid management. As the opioid crisis continues, Nutriband’s leadership in transdermal patch technology offers a promising model for improving patient safety without sacrificing efficacy.

For more information, visit the company’s website at www.Nutriband.com.

NOTE TO INVESTORS: The latest news and updates relating to NTRB are available in the company’s newsroom at https://ibn.fm/NTRB

• The private credit market has experienced remarkable growth over the past decade, evolving from a niche segment to a cornerstone of the financial ecosystem
• FAVO Capital offers a range of financing options, including revenue-based funding and merchant cash advances
• The company’s impact is reflected in its impressive track record of supporting 10,000-plus small businesses, deploying more than $138 million in capital nationwide

In today’s increasingly fragile economic landscape, small and mid-sized businesses (“SMBs”) face mounting challenges in securing the funding necessary for growth and sustainability. Traditional banks, constrained by stringent regulations and risk-averse policies, often fall short in meeting the unique financial needs of these enterprises. This funding gap has paved the way for alternative financing solutions, with private credit emerging as a vital lifeline. Among the key players in this space is FAVO Capital (OTC: FAVO).

The private credit market has experienced remarkable growth over the past decade, evolving from a niche segment to a cornerstone of the financial ecosystem. According to Preqin, private credit assets under management have surged from $500 billion in 2013 to more than $1.7 trillion in 2025, reflecting a compound annual growth rate of approximately 14% (ibn.fm/Tda5P). This expansion is driven by the increasing demand for flexible, non-bank financing options, particularly among SMBs that are underserved by traditional lenders.

SMBs are the backbone of the global economy, accounting for a significant share of employment and GDP. However, they often encounter barriers when seeking financing through conventional channels, such as lengthy approval processes, rigid collateral requirements and limited loan customization. Private credit providers address these challenges by offering tailored financing solutions that align with the specific needs and risk profiles of SMBs. This approach not only enhances access to capital but also fosters innovation and competitiveness within the SMB sector.

FAVO stands out as a leading private credit provider, specializing in delivering fast, efficient and personalized funding solutions to SMBs across the United States and the Dominican Republic (ibn.fm/r3G1p). Leveraging advanced technology and data-driven underwriting processes, FAVO Capital offers a range of financing options, including revenue-based funding and merchant cash advances, designed to accommodate the diverse financial requirements of SMBs.

The company’s commitment to innovation is evident in its integration of fintech solutions that streamline the lending process, enabling quicker decision-making and disbursement of funds. By harnessing artificial intelligence and machine learning algorithms, FAVO Capital enhances its risk assessment capabilities, ensuring more accurate and efficient credit evaluations. This technological edge not only improves the borrower’s experience but also strengthens the company’s portfolio performance (ibn.fm/wSxBW).

FAVO Capital’s impact is reflected in its impressive track record of supporting more than 10,000 small businesses and deploying more than $138 million in capital nationwide (ibn.fm/UEjm1). The company’s strategic focus on underserved markets and commitment to fostering long-term partnerships with clients underscore its role as a catalyst for SMB growth and resilience.

As the private credit market continues to evolve, FAVO Capital is poised to capitalize on emerging opportunities and expand its footprint. The company’s recent initiatives, including a $8 million Series A preferred investment and plans to uplist to the Nasdaq, signal a strong trajectory of growth and institutional engagement (ibn.fm/vEfc4). By staying at the forefront of industry trends and maintaining a client-centric approach, FAVO Capital exemplifies the transformative potential of private credit in empowering SMBs and driving economic progress.

For more information, visit the company’s website at FAVOCapital.com.

NOTE TO INVESTORS: The latest news and updates relating to FAVO are available in the company’s newsroom at https://ibn.fm/FAVO

• The company targets all current ketamine indications, including anesthesia and pain management.
• The U.S. is facing a severe ketamine shortage, prompting NRx to seek priority FDA review.
• NRX-100 eliminates benzethonium chloride, aligning with U.S. health initiatives to remove toxic preservatives.
• The company plans to petition the FDA to remove benzethonium chloride from all intravenous ketamine products.
• The filing complements the company’s NDA for NRX-100 for suicidal depression, with a PDUFA date expected in late 2025.

NRx Pharmaceuticals (NASDAQ: NRXP), a clinical-stage biopharmaceutical company, has filed an Abbreviated New Drug Application with the U.S. Food and Drug Administration for NRX-100, a preservative-free formulation of ketamine. The submission seeks approval for all existing ketamine indications, including its use in anesthesia and pain management (https://ibn.fm/hsgzo).

The move comes amid a significant shortage of ketamine in the United States, as noted by the American Society of Health-System Pharmacists. With demand rising and supply constrained, the company is requesting a priority review from the FDA.

NRX-100 is designed without benzethonium chloride, a compound recognized for its neurotoxic and cytotoxic properties. Its absence positions NRX-100 in line with broader public health efforts to eliminate harmful preservatives from medications. NRx plans to file a citizen’s petition urging the FDA to mandate preservative-free formulations for all ketamine intended for IV use.

The company aims to leverage the existing $750 million U.S. ketamine market and growing global demand, which is projected to reach $3.35 billion by 2034. According to a 2021 survey, an estimated 5.1 million Americans had received ketamine for medical uses in their lifetime, a number that continues to grow. With ketamine use expanding in both hospital settings and psychiatric care, NRx believes NRX-100 could gain traction among providers seeking safer alternatives.

Jonathan Javitt, MD, MPH, Chairman and CEO of NRx Pharmaceuticals, commented on the ANDA submission’s timing in the context of a rapidly expanding market and an inadequate available supply. “We at NRx believe that safer, preservative-free formulations of ketamine will be increasingly preferred by physicians, patients, and regulators in this large and growing market,” Javitt said. “NRX-100 is designed to replace older formulations that rely on potentially neurotoxic and cytotoxic preservatives for stability and sterility. We have filed a U.S. patent on our novel, preservative-free formulation, which anticipates three years of room-temperature shelf stability.”

The move supplements NRx’s New Drug Application (“NDA”) currently underway for NRX-100 in the treatment of suicidal depression. That submission is expected to be reviewed by the FDA in late 2025 under the Prescription Drug User Fee Act (“PDUFA”).

Clinical data backing the NDA includes studies involving more than 1,000 patients and observational data from over 180,000 individuals. The company argues that NRX-100 has demonstrated non-inferiority to electroconvulsive therapy and superiority to both placebo and active placebo in reducing suicidality.

In April 2025, NRx secured a waiver of the $4.3 million NDA filing fee, citing the product’s public health relevance and the company’s small business status. The company was previously granted Fast Track designation for NRX-100 as part of a broader protocol in suicidal bipolar depression.

NRx is also pursuing patent protection for NRX-100, with claims extending through 2045. The formulation is designed to remain stable at room temperature for three years, which the company sees as another advantage over older ketamine products.

The company hopes that its preservative-free formulation can potentially set a new standard for ketamine delivery. In the context of increasing ketamine use for mental health and chronic pain, NRX-100 may become a safer alternative with fewer toxicity concerns. The combination of regulatory positioning, clinical backing, and public health alignment puts NRx in a unique position to compete in a sector undergoing both supply disruption and therapeutic evolution.

For more information, visit the company’s website at www.NRxPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to NRXP are available in the company’s newsroom at https://ibn.fm/NRXP

• The company’s 3.79 MW Geddes facility is expected to begin generating revenue in June 2025.
• The initiative marks one of the first integrations of renewable energy and Bitcoin treasury management.
• Management will determine Bitcoin allocation based on market conditions and operational cash flow.
• The Geddes site, built on a closed landfill, reflects SolarBank’s dual focus on clean energy and land repurposing.
• This move could be extended to other solar and battery energy storage projects across the company’s 1+ GW pipeline.

Disseminated on behalf of SolarBank Corporation

SolarBank (NASDAQ: SUUN) (Cboe CA: SUNN) (FSE: GY2), a premier developer and owner of renewable and clean energy projects, specializing in distributed and community solar initiatives throughout Canada and the U.S., is moving forward with its plan to integrate Bitcoin into its treasury operations by directing net revenue from its soon-to-be-operational Geddes Solar Power Project toward the digital asset. This step marks the company’s first allocation of cash flow to Bitcoin since revealing its treasury strategy earlier in June 2025 (https://ibn.fm/u9bqQ).

The Geddes Project, located in New York State, has a designed capacity of 3.79 megawatts of direct current electricity. Built on a repurposed landfill, the site reflects a broader trend in renewable energy of transforming brownfield sites into productive infrastructure. Once operational, expected before the end of June 2025, the project will sell electricity to local community solar subscribers through power subscription agreements.

After accounting for capital, operating costs, and debt service, net cash generated from the project will be allocated at management’s discretion to purchase Bitcoin. Timing and amounts will depend on market conditions, liquidity needs, and the price of Bitcoin.

SolarBank CEO Dr. Richard Lu described the move as “a sustainable way to add Bitcoin to SolarBank’s balance sheet.” He added that the initiative offers a hybrid approach: combining stable revenue from renewable energy generation with potential upside from holding Bitcoin.

“I am pleased we are moving forward with the first step in our Bitcoin treasury strategy. Geddes is the largest power producing assets that SolarBank will have operational and this strategy provides a sustainable way to add Bitcoin to SolarBank’s balance sheet,” Lu said. “By converting solar energy revenue into digital assets, we’re creating a unique value proposition that combines the stable cash flows of renewable energy with the potential appreciation of Bitcoin, while supporting grid decarbonization and distributed energy resources (‘DER’) expansion.”

The company’s broader strategy involves examining whether additional solar and battery energy storage projects could adopt the same model. As SolarBank continues to scale its operations across North America, this could lead to a more formalized approach to integrating Bitcoin across its clean energy portfolio.

SolarBank currently operates more than 32 MW of installed renewable energy capacity, with a 1+ gigawatt development pipeline in progress. The Geddes Project is the largest asset in its portfolio to date.

The mechanics of the strategy follow a four-step process: solar energy is generated, sold to subscribers, net cash flows to the company, and a portion is used to purchase Bitcoin. This creates two streams of value: predictable energy revenue and Bitcoin holdings.

Bitcoin allocations may be paused, modified, or discontinued based on various business conditions. As of June 4, no purchases have yet been made. Management intends to provide specific allocation percentages after the Geddes Project begins commercial operation.

SolarBank’s move adds a new dimension to ongoing debates around the intersection of digital finance and clean energy. The company is one of the first renewable energy firms to tie Bitcoin directly to revenue from energy production. By allocating surplus cash from clean energy, it aims to balance environmental considerations with financial innovation. With top tier project partnerships, including deals with CIM Group, Qcells, and Honeywell, SolarBank continues to build a portfolio that merges renewable infrastructure with flexible financial planning.

For more information, visit the company’s website at SolarBankCorp.com.

There are several risks associated with the development of the projects detailed in this report. The development of any project is subject to the continued availability of third-party financing arrangements for the project owners and the risks associated with the construction of a solar power project. There is no certainty the projects disclosed in this report will be completed on schedule or that they will operate in accordance with their design capacity.

This report contains forward looking information. Please refer to the press release entitled “Bitcoin Purchases to be made by SolarBank Using Net Cash from Geddes Solar Power Project” for additional details on the statements, risks and assumptions.

NOTE TO INVESTORS: The latest news and updates relating to SUUN are available in the company’s newsroom at https://ibn.fm/SUUN

• The company offers a simple, AI-powered platform that helps providers identify their most valuable services, bringing clarity to complex insurance contracts, and highlighting where clinics can optimize revenue.
• The platform’s AI analytics help to identify high-risk patients and close care gaps efficiently, while letting providers track financial performance over time, aligning income with quality of care.
• Adageis continues to grow and expects to cover 580,000 patient lives by Q2 2025 and reach $100,000 in monthly recurring revenue.

As healthcare shifts further toward value-based care, one challenge continues to frustrate providers: understanding how care quality translates into financial outcomes. Adageis, a growing healthcare technology company with a patented AI-driven platform, is offering providers tools that both simplify operations and improve financial performance under value-based care models.

The platform, rebranded as a fintech AI solution, focuses on helping providers understand how their clinical decisions tie directly to revenue. According to Adageis, three central benefits stand out:

• Ease of use
• Visibility into insurance contracts
• Long-term financial tracking

One of the core advantages Adageis offers is the clarity it brings to complex healthcare systems. Its platform is designed to be simple for clinics to navigate, allowing physicians and administrators to see which of their services yield the highest value. This supports decision-making around treatment priorities while maintaining quality standards.

Instead of relying on outside consultants or navigating spreadsheets, practices can use the software to pinpoint which services align best with revenue and care standards. The platform aims to make this information more accessible to staff without a technical background.

The software supports this by providing direct insight into performance metrics tied to value-based care models, allowing practices to focus on both patient outcomes and financial sustainability.

For many clinics, understanding how much they should be paid under different insurance agreements remains a challenge. Adageis aims to address that, by enabling its software to help providers determine how well they are being compensated for the care they deliver.

This is particularly important for high-performing clinics that may be underpaid for exceeding quality benchmarks. With Adageis, practices can identify which contracts are more favorable and structure their care delivery accordingly.

This functionality also assists newer practices that are transitioning away from fee-for-service models. The platform helps them assess which payer contracts are most lucrative under value-based frameworks, supporting growth without sacrificing quality.

In addition to point-in-time analysis, Adageis helps providers track how their focus on quality care is rewarded financially. By visualizing financial trends alongside patient care metrics, providers can make strategic decisions with better confidence. Clinics can see not just how they’re performing today, but how that performance evolves as care models change.

Beyond software, Adageis positions itself as an advocate for its clients. The company works directly with insurance payers on behalf of providers, helping them navigate negotiations and understand their entitlements. This hands-on approach is especially beneficial for small practices with limited administrative support.

The company also continues to work with investors to expand its offerings, aiming to develop tools tailored to the needs of small and mid-sized clinics.

Adageis’s patented ProActive Care Platform offers full integration with widely used Electronic Health Record (“EHR”) systems including AthenaHealth, Cerner, Epic, and others. This ensures that providers don’t need to overhaul their IT infrastructure to benefit from the system.

Additionally, its Risk Engine (“PRE”) identifies high-risk patients and care gaps, helping clinics deliver timely interventions and reduce avoidable costs. The platform supports proactive care, monitoring patient health beyond traditional office visits.

As of April 2025, Adageis covered over 260,000 patient lives. By the end of Q2, it expects to double that figure to 580,000 and reach $100,000 in monthly recurring revenue. The company also anticipates onboarding two to three new clients each month.

For more information, visit the company’s website at www.Adageis.com.

NOTE TO INVESTORS: The latest news and updates relating to Adageis are available in the company’s newsroom at https://ibn.fm/Adageis

As the world watches Foxconn and NVIDIA deploy smart robotics in Taiwan’s cutting-edge hospitals, the same technology driven future is quietly taking shape across the American hospitality industry. Led by companies like SkyTech Automated Solutions, a wholly owned subsidiary of Nightfood Holdings, Inc. (OTCQB: NGTF).

Foxconn’s recent unveiling of its NVIDIA-powered hospital robots signals a monumental shift: combining real-time AI with robotics to improve labor efficiency, safety, and service personalization. The smart hospital model represents not just a technological leap, but a redefinition of how service delivery is imagined in labor-intensive environments.

SkyTech is bringing that same revolution to the hospitality sector in the United States. Through service robots designed for hotels and restaurants, capable of autonomous delivery, sanitation, guest interaction, and operational logistics, SkyTech is tackling the industry’s labor cost crisis while enhancing guest experience and operational consistency.

Parallel Innovation: Hospitals and Hotels Share the Same DNA

Just as hospitals demand speed, precision, hygiene, and 24/7 service, so too do hotels. The Foxconn-NVIDIA collaboration focuses on surgical-grade robotics in patient-facing roles, like delivery of medicine and disinfection of rooms. Similarly, SkyTech’s hospitality robots automate tasks like:

• Housekeeping logistics — Enabling robotic deployment of linens and trash removal
• Food and beverage Concierge — Aiding the kitchen with hot and cold deliveries right to your door
• AI integrated dusting service — Eliminating the need for manual sweeping

By using edge computing and AI integration, SkyTech is also working toward adaptive intelligence, allowing robots to learn hotel-specific routines and guest preferences over time, increasing value the longer they’re deployed.

National Strategy and the Trump-Era Industrial Reset

The significance of this shift is amplified by macroeconomic and geopolitical context. Under the Trump administration, policies like the Tax Cuts and Jobs Act, tariffs targeting Chinese imports, and efforts to reshore critical manufacturing laid groundwork for a U.S. tech revival. Trump’s push to label robotics and AI as strategic national priorities accelerated capital inflows into sectors like automation, semiconductors, and logistics.

As a result, U.S. manufacturers and tech companies began prioritizing onshore innovation and automation. Robotics companies like SkyTech are direct beneficiaries of that policy environment, able to attract investor attention, partner with American industrial groups, and accelerate AI adoption in areas like hospitality that had long relied on low-wage manual labor.

Automation as a Solution, Not a Threat

While critics worry about job displacement, SkyTech’s deployment model shows the opposite. In hotels facing chronic staffing shortages post-COVID, robots aren’t replacing staff, they’re complementing them. Hotels using SkyTech robots have seen:

• Lower staff turnover, as repetitive labor is reduced
• Increased energy efficiency, through smart environmental control
• Improved hygiene and fewer guest complaints related to room service timing or amenities

Robots handle the boring and the burdensome, while human staff can focus on delivering the high-touch experiences that differentiate top-tier hotels.

The Road Ahead for Nightfood and SkyTech

As Nightfood Holdings builds a vertically integrated hospitality ecosystem, from late-night nutritional offerings to smart robotics, the alignment of SkyTech’s mission with global trends is clear. Like NVIDIA and Foxconn in the medical space, Nightfood and SkyTech are building a next-gen infrastructure for the American hotel sector, driven by automation, AI, and a new national focus on domestic technological leadership.

In the coming years, expect to see SkyTech robots in hundreds of mid-sized hotels and restaurant chains across the U.S., quietly and efficiently redefining what service means in the AI age.

For more information about the company, visit NightfoodHoldings.com.

NOTE TO INVESTORS: The latest news and updates relating to NGTF are available in the company’s newsroom at http://ibn.fm/NGTF

Third-Party Content Disclaimer

The IBN website may contain third-party content articles and other content submitted by third parties, including articles submitted through the IBN Premium Partnership Program. All opinions, statements and representations expressed by such third parties are theirs alone and do not express or represent the views and opinions of IBN or its affiliates and owners. Content created by third parties is the sole responsibility of such third parties, and IBN does not endorse, guarantee or make representations concerning the accuracy and completeness of any third-party content. You acknowledge that by IBN providing you with this internet portal that makes accessible to you the ability to view third party content through the IBN site, IBN does not undertake any obligation to you as a reader of such content or assume any liability relating to such third-party content. IBN expressly disclaims liability relating to such third-party content. IBN and its members, affiliates, successors, assigns, officers, directors, and partners assume no responsibility or liability that may arise from the third-party content, including, but not limited to, responsibility or liability for claims for defamation, libel, slander, infringement, invasion of privacy and publicity rights, fraud, or misrepresentation, or an private right of action under the federal securities laws of the United States or common law. Notwithstanding the foregoing, IBN reserves the right to remove third-party content at any time in its sole discretion. By viewing this third-party content, you acknowledge that you have viewed, read fully, accepted and agreed to all terms of the Disclaimer at https://IBN.fm/Disclaimer.

• Lantern Pharma’s AI-driven RADR(R) platform integrates over 200 billion oncology-specific data points and underpins every stage of its precision oncology pipeline.
• The company has three lead drug candidates in clinical development, targeting major oncology markets including NSCLC, TNBC, and NHL.
• Starlight Therapeutics extends Lantern’s footprint into brain and CNS cancers, including pediatric indications supported by orphan and rare disease designations.
• Lantern has received multiple FDA designations including Fast Track, Orphan Drug, and Rare Pediatric Disease status across its portfolio, enhancing regulatory pathways.
• With approximately $19.7 million in cash and equivalents, the company is funded through at least mid-2026 to support pipeline advancement and platform development.

Lantern Pharma (NASDAQ: LTRN) is a clinical-stage biotechnology company leveraging artificial intelligence and machine learning to redefine oncology drug development. Through its proprietary platform, RADR(R) (Response Algorithm for Drug Positioning & Rescue), Lantern is advancing a pipeline of precision cancer therapies. The company has gained 11 FDA Designations for its portfolio of drug candidates including: Fast Track, Orphan and Pediatric Rare Disease. The company’s data-driven approach enables rapid identification of promising drug candidates and the design of targeted clinical trials for specific patient subpopulations and cancer types.

Lantern’s vision is to transform cancer treatment by integrating large-scale genomics, AI-based biomarker discovery, and preclinical modeling to accelerate the development of oncology drugs. The company’s pipeline includes three lead small molecule candidates and an antibody-drug conjugate (“ADC”) program across 12 cancer indications, supported by strategic collaborations with global research institutions and clinical partners. The company has three active clinical trials enrolling patients with multiple clinical milestones expected throughout the next twelve months.

The company’s mission is centered on transforming the cost and pace of developing innovative therapies for patients with genetically defined cancers or limited treatment options. Lantern is also advancing brain and CNS cancer drug development through its wholly owned subsidiary, Starlight Therapeutics.

The company is headquartered in Dallas, Texas.

Product Portfolio

Lantern Pharma’s product pipeline consists of three lead candidates—LP-300, LP-184, and LP-284—and a preclinical ADC program. All are guided by insights from the RADR(R) platform, which has grown to incorporate over 200 billion oncology-specific data points.

LP-300 is in a Phase 2 trial (Harmonic(TM)) for non-small cell lung cancer (“NSCLC”) in never smokers. The trial evaluates LP-300 in combination with carboplatin and pemetrexed and has shown a clinical benefit rate of 86% and an objective response rate of 43% in its initial cohort. The study is enrolling 90 patients across the U.S., Japan, and Taiwan (NCT05456256).

LP-184 is in a Phase 1a trial for advanced solid tumors and GBM (NCT05933265). The compound has received FDA Fast Track Designations for GBM and triple-negative breast cancer (“TNBC”), as well as four Rare Pediatric Disease Designations. Upcoming Phase 1b/2 trials are planned for TNBC (monotherapy and with olaparib) and for NSCLC patients with KEAP1/STK11 mutations in combination with nivolumab and ipilimumab.

LP-284 is currently in a Phase 1 trial for relapsed or refractory non-Hodgkin’s lymphoma (“NHL”) and other solid tumors (NCT06132503). The drug candidate has demonstrated complete tumor suppression in preclinical models of mantle cell lymphoma resistant to Ibrutinib and bortezomib and showed synergistic activity with rituximab in high-grade B-cell lymphoma models.

Lantern’s ADC program is based on cryptophycin conjugates and is undergoing preclinical evaluation, showing sub-nanomolar potency and improved targeting in HER2-expressing models.

The company has also launched Starlight Therapeutics, focused on CNS cancers, where STAR-001 (LP-184 for CNS cancers) is advancing toward a Phase 1b/2 trial in glioblastoma and pediatric brain cancers, including ATRT, supported by Rare Pediatric Disease Designations and preclinical validation from Johns Hopkins.

Market Opportunity

Lantern Pharma is focused on oncology indications with significant unmet medical need and multi-billion-dollar commercial potential.

• LP-300 targets non-small cell lung cancer in never smokers, a patient population estimated at over 150,000 cases globally and representing a market opportunity exceeding $4 billion annually.
• LP-184 is positioned for use in DDR-deficient tumors such as pancreatic, bladder, and triple-negative breast cancers, which collectively represent a U.S. market opportunity estimated at over $10 billion annually. Opportunities in targeted DDR-deficient tumors include the KEAP1/STK11 mutant NSCLC population targeted by LP-184, with a market potential of over $2 billion annually, and TNBC, which alone represents a $4 billion global market given its aggressiveness and high brain metastasis rate.
• LP-284 is aimed at relapsed or refractory non-Hodgkin’s lymphomas, particularly mantle cell lymphoma and HGBL, within a market sized at $3.5 to $4 billion globally.
• CNS cancers addressed by Starlight Therapeutics further expand Lantern’s reach, representing an estimated $5 billion annual global opportunity, including both adult and pediatric cancers.

Leadership Team

Panna Sharma, President, Chief Executive Officer, and Director, leads Lantern Pharma with a deep background in oncology-focused biotechnology and artificial intelligence. He is responsible for Lantern’s strategic vision and has driven the growth of its AI-powered drug development platform. Prior to joining Lantern in 2018, he served as President and CEO of Cancer Genetics Inc. (NASDAQ: CGIX), where he raised over $100 million and expanded the company from 25 to over 250 employees across multiple continents. Earlier, he founded TSG Partners and played a key role in the IPO of iXL, a digital strategy firm.

David R. Margrave, Chief Financial Officer and Secretary, has served in executive roles in life sciences for over two decades. Before joining Lantern, he held leadership positions at BioNumerik Pharmaceuticals, including President and Chief Administrative Officer. He has also been a strategic consultant to multiple biotech firms and served as Senior Legal Advisor at MedCare Investment Corporation. Mr. Margrave holds a dual degree in Economics and Petroleum Engineering from Stanford University and a J.D. from The University of Texas School of Law.

Kishor G. Bhatia, Ph.D., Chief Scientific Officer, has more than 40 years of experience in cancer biology, including leadership at the National Cancer Institute where he served as Director of the AIDS Malignancy Program and held key roles in cancer treatment and diagnosis. He has also worked as an Adjunct Investigator and consultant to biotech firms such as Reprocell and Cancer Genetics. Dr. Bhatia earned his Ph.D. in Biochemistry from the University of Mumbai and completed postdoctoral research at Johns Hopkins University. He is a Fellow of the Royal College of Pathology in the UK.

For more information, visit the company’s website at www.LanternPharma.com.

NOTE TO INVESTORS: The latest news and updates relating to LTRN are available in the company’s newsroom at https://ibn.fm/LTRN